EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Adaptimmune Therapeutics (NASDAQ:ADAP) and maintained a $10 price target.
August 10, 2023 | 8:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on Adaptimmune Therapeutics and maintained a $10 price target, potentially indicating positive sentiment towards the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. A reiterated 'Buy' rating and maintained price target from a reputable analyst like EF Hutton suggests confidence in the company's performance, potentially leading to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100